Conference Proceedings

Phase I/II study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody BGB-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors

J Desai, M Voskoboynik, B Markman, J Hou, D Zeng, T Meniawy

Annals of oncology : official journal of the European Society for Medical Oncology | OXFORD UNIV PRESS | Published : 2018

DOI: 10.1093/annonc/mdy279.431

University of Melbourne Researchers

Grants

Funding Acknowledgements

BeiGene, Ltd.

Citation metrics

1Web of Science
1Dimensions

Keywords

Immunotherapy
6.2 Cellular and Gene Therapies
Clinical Research
Clinical Trials and Supportive Activities
3211 Oncology and Carcinogenesis
Science & Technology
Immunization
Biotechnology
Life Sciences & Biomedicine
32 Biomedical and Clinical Sciences
Oncology
3204 Immunology